Vimarsana
Biggest News Aggregation in the World

Page 2 - Ctla 4 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ctla 4. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ctla 4 Today - Breaking & Trending Today

Researchers identify mechanism that causes gastrointestinal problems with cancer immunotherapy - Vimarsana News

Researchers identify mechanism that causes gastrointestinal problems with cancer immunotherapy

Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment.

Anti-CTLA-4 nanobodies offer promising strategy to prevent colitis in cancer immunotherapy - Vimarsana News

Anti-CTLA-4 nanobodies offer promising strategy to prevent colitis in cancer immunotherapy

Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 antibodies induce inflammatory toxicities during antitumor immune checkpoint inhibitor therapies.

Triple Combination Therapies in RCC: Clinical Trial Insights - Vimarsana News

Triple Combination Therapies in RCC: Clinical Trial Insights

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

ANU research uncovers protein's role in autoimmune disease and cancer - Vimarsana News

ANU research uncovers protein's role in autoimmune disease and cancer

A protein in the immune system programmed to protect the body from fungal infections is also responsible for exacerbating the severity of certain autoimmune diseases such as irritable bowel disease (IBS), type 1 diabetes, eczema and other chronic disorders, new research from The Australian National University (ANU) has found.

Patient Eligibility for Utilizing Anti-CTLA4-Containing Regimens - Vimarsana News

Patient Eligibility for Utilizing Anti-CTLA4-Containing Regimens

A conversation on patient tolerance of CTLA-4 immunotherapies, alongside an exploration of treatment-related adverse reactions is discussed by a panel of experts.

Source: ajmc.com